The Clinical Pharmacokinetics of Cladribine

  title={The Clinical Pharmacokinetics of Cladribine},
  author={Jan O. Liliemark},
  journal={Clinical Pharmacokinetics},
  • J. Liliemark
  • Published 1 February 1997
  • Medicine, Biology
  • Clinical Pharmacokinetics
SummaryCladribine is a new purine nucleoside analogue with promising activity in low-grade lymphoproliferative disorders, childhood acute myelogenous leukaemia and multiple sclerosis. Reversed phase high performance liquid chromatography and radioimmunoassay have been used for the analysis of the plasma pharmacokinetics of cladribine. The major (inactive) metabolite in plasma, chloroadenine, can only be detected by liquid chromatography.The oral bioavailability of cladribine is 37 to 51%, and… 

Cladribine: a review of its use in multiple sclerosis.

  • H. LangtryH. Lamb
  • Medicine
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • 1998
Cladribine therapy appears to have the potential to slow the progression of MS, reduce CNS lesions in patients with either the chronic progressive or relapsing-remitting forms of the disease and improve neurological functioning in some of these patients.

Pharmacokinetic Study and Toxicity of Leukovir: A New Combined Drug for the Treatment of Multiple Sclerosis

Distribution and accumulation parameters (V d, V ss and AUC) have indicated that the drug distribution between the blood cells and blood plasma takes place in the same way, irrespective of the dosage form.

Cladribine to Treat Relapsing Forms of Multiple Sclerosis

Data from the oral cladribine extension trial and safety register, and reanalysis of the pivotal phase III trial has indicated that oralcladribine is unlikely to be associated with an increased short- to intermediate-term risk of malignancy.

Cladribine for multiple sclerosis: review and current status

  • J. Sipe
  • Medicine
    Expert review of neurotherapeutics
  • 2005
The proposed study will be the first large multicenter randomized controlled clinical trial of oral cladribine in multiple sclerosis, with evidence of efficacy, tolerability and acceptable side effects/toxicity.

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis

Both CdA and CAde displayed linear PK after intravenous and oral administration of C dA, with Cd a renal function depending on CLCR, and a one-compartment model best described the PK of C Ade.

Immunomodulatory Effects Associated with Cladribine Treatment

Data indicate that cladribine, in addition to its cytotoxic function, can mediate immunomodulation in different immune cell populations, by regulating their proliferation, maturation and activation.

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

A review of all safety data, including lymphopenia, infections, and malignancies, is provided based on data from all trials in patients with MS, including the initial parenteral formulation studies.

Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine

In vitro studies examining the inhibitor characteristics of cladribine for a total of 13 major ATP-binding cassette, solute carrier, and CNT transporters indicate that in vivo inhibition of any of thesetransporters bycladribine is unlikely.

Phase I trial of nelarabine in indolent leukemias.

  • V. GandhiC. Tam M. Keating
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
Nelarabine is an effective regimen against indolent leukemias, and combining it with fludarabines was most promising, and determination of tumor cell ara-GTP levels may provide a predictive test for response to nelarABine.

Radioiodination and biological evaluation of Cladribine as potential agent for tumor imaging and therapy

The good uptake of 125I-Cladribine confirms the molecular docking studies results which indicate that iodinated Clad Ribine binds with polymerase enzyme with a good –CDOCKER energy, and may be used as a valuable agent for tumor diagnosis and therapy.



Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.

Data suggest that cladribine may be useful in the treatment of patients with meningeal leukemia or malignancies of the central nervous system and the first comprehensive description of the pharmacokinetics of this drug in children is provided.

Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Should early response rates in patients with hairy cell leukaemia be sustained, the efficacy of the drug, together with a short treatment regimen, a favourable tolerability profile, and the possibility of oral therapy, suggest that cladribine is likely to supersede other agents available for this indication.

Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.

In all patients with leukemia, the CdA lowered the blast count by at least 50%, and in one patient with a T-cell leukemia-lymphoma, and in another patient with chronic myelogenous leukemia in blast crisis, theCdA infusion eliminated all detectable blasts from the blood and bone marrow.

Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.

The insertion of two analogs in sequence, inhibition of ribonucleotide reductase, and the metabolic potentiation of ara-CTP by CdA infusion may be responsible for sustained inhibition of DNA synthesis in the circulating leukemia blasts during therapy with this combination regimen.

On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans.

The long terminal half-life of CdA after 2-h infusion supports the use of intermittent infusions, and the interindividual variability of the determinants of the plasma pharmacokinetics of CcdA was small.

Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia.

Orally administered cladribine is an effective and feasible therapy for CLL, and produces durable remissions in three quarters of the patients, however, significant toxicity may occur and further studies are required to assess long-term effects and quality-of-life aspects.

A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.

The results of this study confirm the antileukemic activity of 2-CDA and the lack of prohibitive nonhematologic toxicity, and phase II trials in patients with AML and ALL are warranted.

Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.

Subcutaneous injection of CdA is safe and as effective as continuous infusion without problems associated with the mode of administration and can be generally recommended.

2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.

2-CDA given by prolonged continuous infusion has clinically significant activity against AML and merits further testing in multidrug regimens for this disease.

2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.

These results establish the major activity of 2-CdA in patients with untreated indolent lymphoma, especially those with the diffuse small lymphocytic subtype.